2026 Day 2 AgendaTuesday, 28 April 2026 - ET (Eastern Time, GMT-05:00)

• Audience icebreaker activities during the Chair’s opening session

• FCPA takeaways for updating risk management, internal investigations and compliance strategies
• Navigating tariffs and sanctions - how are compliance teams adapting to new geoeconomics trends
• What does it now take to manage a global team, keep everyone on the same page and tackle compliance calls?
• Establishing compliance standards across varied geographies: developing a core program with regional flexibility

• Collaborating with HR to integrate compliance into a company’s culture and foster an inclusive and engaged workplace
• Why and when employees feel comfortable speaking up
• Practical strategies to empower employees
• Insights from recent government guidelines on fostering a strong compliance culture
• Proactive steps to identify and address issues before they escalate

• Decoding OIG enforcement: scrutinizing recent OIG settlements and their implications

• Turning guidance into controls: aligning programs with OIG’s guidance and recent advisory opinions

• Commentary on the latest developments from DOJ
• Update on DOJ’s health care fraud, FCPA, and other corporate enforcement
• DOJ guidance to prosecutors and its significance for pharmaceutical companies
• The current state of False Claims Act litigation

• Analysis of the most recent Executive Orders impacting (Bio)pharmaceutical companies
• Implications of the Big, Beautiful Bill and Most Favoured Nations Pricing
• Update on FDA activity
• Litigation against the Administration

Compliance is shifting from dashboards to decisions, from detection to prevention. This session spotlights how leading organizations are using AI to transform fragmented audit, monitoring and investigations data into actionable insights that drive faster, smarter risk decisions. Through real-world case studies, we’ll explore what’s working now and what’s next.

You’ll hear how companies are:

• Using AI-driven analytics to flag anomalies, detect emerging risks, and optimize field and digital monitoring.

• Turning disparate data into prioritized risk insights that guide proactive action.

• Building right-sized, cost-effective AI capabilities across pharma and biotech.

• Leveraging automation to reduce investigation time, cut costs, and improve accuracy.

• Harnessing predictive analytics and GenAI to shape the future of compliance operations.

• How can we ensure we are communicating in every way we can communicate whilst remaining compliant?
• Interactions with GPOs – examining the types of interactions with field roles, what they can talk about and what can they do
• Medical commercial interactions: helping Compliance keep pace with agile approaches
• Considerations when using scientific platforms to engage HCPs

Get inspired with three rapid-fire, 10-minute case studies that deliver actionable insights. Learn how industry leaders tackle real-world challenges, uncover upside opportunities, and optimize resources for success.